Monopar delays IPO again despite slashing offering while a micro-cap biotech clinches $9M
Two low-profile budget biotechs have become the latest casualty of a weak IPO market. Monopar Therapeutics is postponing its public debut for a second time, whereas CNS Pharmaceuticals raised a meager $9 million by pricing at the low end of the range.
By the time Monopar came around to filing its second pitch, it had already slashed its goal (and the number of shares offered) by half — seeking to bag $20 million instead of $40 million it had originally proposed in August. But even that proved to be a stretch.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.